A Rare Case of Idiopathic Intracranial Hypertension with Anemia: A Case Report

Authors
Aaminah Najmus Sahar*, Khadija Akhtar Omer, Neha Naaz, Sufia Iram Irshad
Department of Pharmacy Practice, Deccan School of Pharmacy (DSOP), OU, Hyderabad-500001, Telangana, India
*Corresponding Author
Aaminah Najmus Sahar

Abstract
Idiopathic Intracranial hypertension (IIH) is a condition characterized by elevated Intracranial pressure (ICP) due to no definite cause. It is a rare disorder and mostly occurs in females of reproductive age and obese individuals. Obesity and anemia are associated with elevated ICP, and contribute to the disease. If not managed at right time prolonged ICP can lead to papilledema and other visual abnormalities. The diagnosis is made with MRI, CT scan, lumbar puncture. The treatment focuses on reducing the elevated ICP and preserving the optic nerve function. Treatment is done with pressure reducing agents like Acetazolamide and supportive treatment may be given to reduce headache. This disease is prone to recurrence, thus management of weight and lifestyle modifications are necessary to prevent the relapse of disease.

Keywords: Idiopathic Intracranial Hypertension (IIH), Intracranial pressure (ICP), Acetazolamide, Obesity, Papilledema.

Introduction
Idiopathic Intracranial hypertension (IIH) is a condition characterized by increased Intracranial pressure (ICP) around the brain without a definite detectable cause. It is also known as pseudotumor cerebri and benign intracranial hypertension (BIH), but IIH is the most widely used term. It occurs without a known cause and is known to occur more commonly in obese females in the reproductive age (i.e. the third decade of life). However it can occur in males and females of all ages and body types. Risk factors for IIH include Hypervitaminosis A, steroid withdrawal, obesity, female gender, pregnancy.[1] The incidence of IIH has increased since 1990, which is highly correlated with the rise in obesity during the same period.[2]

The primary problem is chronically elevated intracranial pressure (ICP), and the most important neurologic manifestation is papilledema, which may lead to secondary progressive optic atrophy, visual loss, and possible blindness.[3] Anemia may also play a role in the occurrence of raised ICP and papilledema though the underlying mechanism is not exactly known.[4] The characteristics signs and symptoms include-headache, visual loss, transient visual obscuration, diplopia, pulsatile tinnitus, radicular pain and non specific symptoms like nausea and vomittings. Diagnosis is made with the help of
The goal of treatment is to manage the increased ICP and to preserve the optic nerve function. The standard treatment includes\(^5\): - Acetazolamide- It is the first line therapy in the treatment of increased ICP and IIH. Acetazolamide appears to have an acceptable safety profile at dosages up to 4 g/d in the treatment of idiopathic intracranial hypertension.\(^6\) - Diuretics- Considered as second line agents in treatment of IIH. - Headache Prophylaxis- Amitriptyline and other anti migraine agents may be required to reduce the headache. - Corticosteroids- To increase the elevated IIH. If there is no symptomatic improvement in patient after the treatment, surgical interventions maybe required.

**Case Report**

A 33 Year old female was brought to the Neurology department with the complaints of Headache since 1 year which is now increased since past 2 months. Headache is of hemi, holocranial type and episodic (2-3 times/week). It is accompanied with nausea, vomittings and phonophobia. Headache increases in recumbent position. Intermittent visual blurring also seen. The patient has no other comorbidities and no history of Stroke, Loss of consciousness and Seizures in the past. The patient has a mixed diet, normal appetite, normal bladder and bowel functions and sound sleep. On hospital admission the systemic examination showed the following-Temperature: Normal, Blood pressure: 120/80, Pulse rate: 80 beats/min, Respiratory rate:20/min, CNS: Alert, Oriented, No focal deficits.

**Treatment**

Anti-migraine agents- Tablet Naproxen + Domperidone – 250mg –Oral –SOS was given to reduce headache. Pressure reducing agents- Tablet Acetazolamide-250mg –Oral-twice a day was given to reduce the elevated ICP causing IIH. Mood elevating agent- Tablet Levosulpiride-100mg –Oral-twice a day was given to reduce patients headache and elevate mood. Electrolyte balance – IV fluid Normal Saline was transfused intravenously at the rate of 30ml per hour. Ulcer prophylaxis- Inj Pantoprazole – 40mg –IV was given once a day as an ulcer prophylaxis. Multivitamins – Tablet Multivitamin was given once a day to reduce weakness in the patient. Iron- Tablet Ferrous Ascorbate + Folic acid -100mg –Oral –once a day was given to treat Anemia.

**Table 1 Medication Chart**

| S.No: | DRUG                              | DOSE     | ROUTE     | FREQUENCY     |
|------|-----------------------------------|----------|-----------|---------------|
| 1.   | Injection Pantoprazole           | 40mg     | Intravenous | Once a day    |
| 2.   | Tablet Levosulpiride             | 100mg    | Oral      | Twice a day   |
| 3.   | Tablet Naproxen+Domperidone      | 250mg    | Oral      | SOS           |
| 4.   | IVF Normal Saline                | 30ml     | Intravenous | Per hour   |
| 5.   | Tablet Multivitamin              | 1 tablet | Oral      | Once a day for 2 months |
| 6.   | Tablet Acetazolamide             | 250mg    | Oral      | Twice a day   |
| 7.   | Tablet Ferrous Ascorbate + Folic acid | 100mg | Oral | Once a day |

**Day 2 –**

Patients vitals were as follows-
Temperature-Normal, BP-11/80mmHg, Pulse- 80 beats/min, Respiratory rate-20/min, GRBS- 106 mg/dl.
Patient has no new complaints. Headache is better than before. Patient is alert, no focal deficits.

**Day 3 –**

Patients vitals were as follows-
Temperature-Normal, BP-130/70mmHg, Pulse-80 beats/min, Respiratory rate- 20/min. Patient has a mild, intermittent headache. Patient is alert, oriented, obeying commands. Patient was discharged on request.
**Table 2** Complete Blood Picture

| S.No. | Laboratory Data   | Day 1       | Normal Value       |
|-------|------------------|-------------|--------------------|
| 1.    | Haemoglobin      | 8.9 gm/dl  | 11-17 gm/dl        |
| 2.    | Red blood cells  | 3.90 million/cumm | 3.7-6.5 million/cumm |
| 3.    | White blood cells| 9,330 cells/cumm | 4000-11000 cells/cumm |
| 4.    | Neutrophils      | 65%        | 40-80%             |
| 5.    | Lymphocytes      | 26%        | 20-40%             |
| 6.    | Monocytes        | 5%         | 2-10%              |
| 7.    | Eosinophils      | 4%         | 1-6%               |
| 8.    | Basophils        | 0%         | <1-2%              |
| 9.    | Platelets        | 4.53 lakhs/cumm | 1.5-4 lakhs/cumm |

**Table 3** Serum Electrolytes

| S.No. | Laboratory Data | Day 1       | Normal Values       |
|-------|-----------------|-------------|--------------------|
| 1.    | Sodium          | 137 mmol/L  | 135-145 mmol/L     |
| 2.    | Potassium       | 4.2 mmol/L  | 3.5-5 mmol/L       |
| 3.    | Chloride        | 102 mmol/L  | 95-105 mmol/L      |

**Table 4** Liver Function Test

| S.No. | Laboratory Data | Day 1       | Normal Values       |
|-------|-----------------|-------------|--------------------|
| 1.    | Total Protein   | 7 gm/dl     | 6-7.5 gm/dl        |
| 2.    | Albumin         | 4.4 gm/dl   | 3.5-5 gm/dl        |
| 3.    | Total Bilirubin | 0.3 mg/dl   | 0.2-1.0 mg/dl      |
| 4.    | Direct Bilirubin| 0.1 mg/dl   | Upto 0.2 mg/dl     |
| 5.    | SGOT            | 15 U/l      | 5-45 U/l           |
| 6.    | SGPT            | 16 U/l      | 5-45 U/l           |
| 7.    | Alkaline Phosphatase | 91 U/l | 35-104 U/l |

**Table 5** Biochemistry

| S.No. | Laboratory Data | Day 1       | Normal Value       |
|-------|-----------------|-------------|--------------------|
| 1.    | Random Blood Sugar | 96 mg/dl   | 6-150 mg/dl        |
| 2.    | Serum Creatinine | 0.6 m/dl   | 0.6-1.5 mg/dl      |

**Discussion**

Idiopathic intracranial hypertension (IIH) is a rare condition occurring usually in females of reproductive age. Though it can happen to both males and females of all ages, people with obesity, female gender, steroid withdrawal and pregnant women are at greater predisposition. The main concern in Idiopathic intracranial hypertension is the elevated Intracranial pressure (ICP) and treating this helps in resolving of IIH. Obesity and Anemia are known to cause elevated Intracranial pressure (ICP). Although the exact underlying mechanism remains unknown, treatment of Anemia and reduction of obesity was found to reduce the ICP thereby resolving IIH. If not managed at time the elevated ICP can cause papilledema and other visual abnormalities. The standard treatment for IIH includes a pressure reducing agent like Acetazolamide, Analgesics to reduce headache, Iron supplementation if patient is anemic, Multivitamins and electrolyte replenisher to treat weakness. Recurrence of the disease is common in patients with IIH, thus it is necessary to maintain a healthy weight and Hb levels, take a healthy diet rich in fruits and vegetables, avoid fatty and processed food, exercise regularly and take periodic ophthalmological consultations.

**Conclusion**

The exact etiology of Idiopathic Intracranial hypertension remains unknown, but avoiding the risk factors helps in preventing the disease to a great extent. Complications like vision loss can also be avoided by timely management of the disease. Lifestyle modifications and weight management also help in management of disease and prevent its recurrence.

**References**

1. Idiopathic Intracranial Hypertension-Michael Wall MD-Elsevier-Volume 9, Issue 1, Feb 1991
2. Re-evaluating the Incidence of Idiopathic Intracranial Hypertension in an Era of Increasing Obesity-Kilgore KP1, Lee MS2, Leavitt JA3, Mokri B4, Hodge DO5, Frank RD6, Chen JJ7. Elsevier –May 2017.
3. The Rational Management of Idiopathic Intracranial Hypertension-James J.
Corbett, MD; H. Stanley Thompson, MD-JAMA Neurology-October 1989.

4. Anemia and papilledema.-Biousse V, Rucker JC, Vignal C, Crassard I, Katz BJ, Newman NJ.- Am J Ophthalmol. 2003 Apr;135(4):437-46.

5. Idiopathic intracranial hypertension: consensus guidelines on management-Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, Krishnan A, Chavda SV, Ramalingam S, Edwards J, Hemmings K, Williamson M, Burdon MA, Hassan-Smith G, Digre K, Liu GT, Jensen RH, Sinclair AJ.- J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1088-1100. doi: 10.1136/jnnp-2017-317440. Epub 2018 Jun 14

6. Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial-ten Hove MW, Friedman DI, Patel AD, Irrcher I, Wall M, McDermott MP; NORDIC Idiopathic Intracranial Hypertension Study Group.- J Neuroophthalmol. 2016 March.